Turaev Bobur, Ibragimov Nodir, Babaev Afzal, Turaeva Yulduz, Khaydarov Kambarali
Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan.
Kardiochir Torakochirurgia Pol. 2025 Mar;22(1):14-19. doi: 10.5114/kitp.2025.148562. Epub 2025 Mar 17.
Pulmonary artery (PA) repair in pediatric cardiac surgery often utilizes the transannular patch (TAP) technique, which, while effective, is associated with complications such as right ventricular (RV) dysfunction and pulmonary valve (PV) regurgitation.
Recent findings highlight the need for improved strategies to address these issues and enhance long-term outcomes.
This retrospective cohort study analyzed 16 pediatric patients who underwent PA repair between December 2023 and April 2024. Patients were divided into two groups: right atrial appendage (RAA) neovalve ( = 8) and TAP ( = 8). Key procedural metrics, RV function, and postoperative outcomes were evaluated using standard statistical methods.
The RAA neovalve group demonstrated significantly reduced severe PV regurgitation compared to the TAP group ( < 0.001). Additionally, the RAA neovalve group exhibited improved RV function, with more patients showing no RV dysfunction ( = 0.014). The RAA neovalve group also experienced shorter ICU stays (3.88 ±0.84 days vs. 6.13 ±2.75 days, = 0.044) and hospital stays (10.1 ±1.25 days vs. 13.2 ±3.19 days, = 0.029).
The RAA neovalve technique presents a significant improvement over traditional TAP in reducing severe PV regurgitation and enhancing RV function. The shorter ICU and hospital stays associated with the RAA neovalve suggest better postoperative recovery. These results indicate that the RAA neovalve could be a superior alternative to TAP for PA repair, warranting further research to confirm these benefits and explore long-term outcomes.
小儿心脏手术中的肺动脉（PA）修复通常采用跨环补片（TAP）技术，该技术虽然有效，但会引发诸如右心室（RV）功能障碍和肺动脉瓣（PV）反流等并发症。
近期研究结果凸显了改进策略以解决这些问题并改善长期预后的必要性。
这项回顾性队列研究分析了2023年12月至2024年4月期间接受PA修复的16例儿科患者。患者分为两组：右心耳（RAA）新瓣膜组（n = 8）和TAP组（n = 8）。使用标准统计方法评估关键手术指标、RV功能和术后结果。
与TAP组相比，RAA新瓣膜组的重度PV反流明显减少（P < 0.001）。此外，RAA新瓣膜组的RV功能有所改善，更多患者未出现RV功能障碍（P = 0.014）。RAA新瓣膜组的重症监护病房（ICU）住院时间也更短（3.88±0.84天 vs. 6.13±2.75天，P = 0.044），住院时间也更短（10.1±1.25天 vs. 13.2±3.19天，P = 0.029）。
RAA新瓣膜技术在减少重度PV反流和改善RV功能方面比传统TAP有显著改进。与RAA新瓣膜相关的较短ICU和住院时间表明术后恢复更好。这些结果表明，RAA新瓣膜可能是PA修复中TAP的更好替代方案，值得进一步研究以证实这些益处并探索长期预后。
